前列腺癌、乳腺癌、卵巢癌和/或胰腺癌家族史与大型前列腺癌主动监测队列中分级重新分类的关联
本研究在前瞻性主动监测队列(N=1421)中评估前列腺癌、乳腺癌、卵巢癌和/或胰腺癌家族史与分级重新分类的关联。中位随访期间,前列腺癌家族史与重新分类至GG≥2和GG≥3的风险增加相关(GG≥3的调整HR为1.49,95%CI 1.02-2.17,p=0.039),而乳腺癌、卵巢癌和/或胰腺癌家族史无显著关联。有家族史的患者可安全进行主动监测,但可能需要更密切的监测。
要点
- 前列腺癌家族史与主动监测中分级重新分类至GG≥3风险增加相关(HR 1.49)。
- 乳腺癌、卵巢癌和/或胰腺癌家族史与分级重新分类无显著关联。
- 任何家族史状态均与根治性前列腺切除术后的不良病理特征无关。
核心结论
- 有前列腺癌家族史的患者主动监测中分级重新分类风险更高,包括极端分级重新分类(GG≥3),但无家族史状态导致更多根治性前列腺切除术后的不良病理特征。
研究设计与样本
- 前瞻性主动监测队列研究,纳入1421例有家族史记录的患者。
- 采用竞争风险分析评估家族史与分级重新分类的关联,多变量逻辑回归评估不良病理特征。
主要发现
- 1421例患者中,有前列腺癌家族史者41/362(11.3%)重新分类至GG≥3,有乳腺癌、卵巢癌和/或胰腺癌家族史者37/336(11.0%),有任一上述家族史者67/600(11.2%)。
- 前列腺癌家族史与重新分类至GG≥2和GG≥3相关(GG≥3的调整HR 1.49,95%CI 1.02-2.17,p=0.039)。
- 前列腺癌和/或乳腺癌、卵巢癌、胰腺癌家族史与GG≥3重新分类相关(HR 1.52,95%CI 1.07-2.17,p=0.020)。
- 乳腺癌、卵巢癌和/或胰腺癌家族史与任何分级重新分类无关(GG≥3的HR 1.30,95%CI 0.88-1.94,p=0.190)。
- 349例接受根治性前列腺切除术的患者中,无家族史状态与不良病理特征相关。
临床怎么用
- 有前列腺癌家族史的患者可安全进行主动监测,但可能需要更密切的监测。
局限性
- 研究仅有一级亲属的家族史信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The effect of family history (FH) on prostate cancer active surveillance outcomes is unknown. Our objective is to evaluate FH of prostate, breast, ovarian, and/or pancreatic cancer in a large prospective active surveillance cohort. METHODS: Patients with recorded FH data (N = 1421) were selected. Association between grade reclassification to Gleason grade (GG) ≥2 and GG ≥3, and FH of prostate cancer (FH-Pr); FH of breast, ovarian, and/or pancreatic cancer (FH-BOPa); and FH-Pr and/or FH-BOPa in first-degree relatives was evaluated by a competing risk analysis. Association with adverse pathologic features (APFs; GG ≥3, seminal vesicle, and/or lymph node involvement) at radical prostatectomy was assessed with multivariable logistic regression. KEY FINDINGS AND LIMITATIONS: Of the 1421 patients, 41/362 (11.3%) with FH-Pr, 37/336 (11.0%) with FH-BOPa, and 67/600 (11.2%) with FH-Pr and/or FH-BOPa were reclassified to GG ≥3. FH-Pr was associated with reclassification to GG ≥2 and GG ≥3 (adjusted hazard ratio [HR] 1.49 for GG ≥3 [95% confidence interval {CI} 1.02-2.17], p = 0.039), as was FH-Pr and/or FH-BOPa (HR 1.52 for GG ≥3 [95% CI 1.07-2.17], p = 0.020). FH-BOPa however was not associated with any grade reclassification (HR 1.30 for GG ≥3 [95% CI 0.88-1.94], p = 0.190). In the 349 patients who underwent radical prostatectomy, no FH status was associated with APFs. Our study is limited by having information on first-degree relatives only. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients with FH-Pr had a higher risk of grade reclassification, including extreme grade reclassification (GG ≥3), but no FH status led to more APFs at radical prostatectomy. Patients with FH can safely be managed on surveillance, but might benefit from closer monitoring.
引用
- de la Calle CM, Jing Y, Fountain J, et al. Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort. Eur Urol Oncol. 2025. PMID: 40914661. doi:10.1016/j.euo.2025.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。